All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is HSCT an option for refractory AML?
Bookmark this article
During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the AML Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked: Is HSCT an option for refractory AML?
Is HSCT an option for refractory AML?
Mohamad Mohty emphasizes the poor prognosis and the lack of available options in the settings of primary refractory or relapsed/refractory AML. He describes allo-HSCT as the only curative approach when it is feasible and patients deemed fit for it, and discusses that the use of allo-HSCT is becoming more common and results are improving over time.
Your opinion matters
1 vote - 2 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox